Clinical trials showed a 50% discontinuation of treatment within the first 8 weeks of therapy. This was due to several challenges: difficulty staying adherent to 2x daily oral oncolytic, older age of the patient population, and side effects.

Develop a patient community to seamlessly onboard patients to their oral oncolytic, provide educational content and insights to address their questions, and connect them with peers & community managers to leave ‘no patient alone’

– AI matched patients for peer mentorship
– Proactively educate on side effects
– Push notifications for medication adherence & tracking
– PSP connectivity cross-validated patient status
– PSP ID used as gating mechanism

86% of patients in app monthly
71% of patients stayed on therapy past 8-week checkpoint
73% of patients said the app helped them better manage and report side effects
70% of patients digested 4 educational health programs